Creutzfeldt-Jakob disease (CJD) is a rare, fatal brain disorder caused by misfolded proteins called prions. It affects roughly 1 to 2 people per million each year worldwide, translating to an estimated 8,000 or more cases globally. CJD destroys brain tissue rapidly, and most people with the most common form survive only about five months after symptoms appear, though some live a year or longer.
How Prions Damage the Brain
Your brain naturally contains a normal, harmless version of the prion protein on the surface of nerve cells. In CJD, that protein gets refolded into an abnormal shape. The misfolded version is insoluble and resistant to the enzymes that would normally break it down, so the body can’t clear it. Worse, it acts like a template: when it comes into contact with normal prion proteins, it converts them into copies of itself. This chain reaction accelerates over time.
As misfolded prions accumulate, they cluster into clumps that damage and kill neurons. The dying neurons leave behind tiny holes in brain tissue, giving it a sponge-like appearance under a microscope. This “spongiform” destruction is the hallmark of prion diseases and is ultimately what drives every symptom of CJD, from memory loss to the inability to move or speak.
The Four Types of CJD
Not all cases of CJD arise the same way. The disease falls into four categories based on how the misfolding process begins.
Sporadic CJD
This is by far the most common form, accounting for the vast majority of cases. It appears to happen spontaneously, with no identifiable cause. The prion protein simply misfolds on its own, for reasons that remain unclear. Sporadic CJD typically strikes people over the age of 60.
Familial (Inherited) CJD
About 10 to 15 percent of prion disease cases are inherited. These are caused by mutations in the PRNP gene on chromosome 20, which carries the instructions for making the prion protein. The most common culprit is a specific point mutation known as 200K, responsible for more than 70 percent of hereditary CJD families worldwide. The mutations follow an autosomal dominant pattern, meaning a child of someone carrying the mutation has a 50 percent chance of inheriting it. Other inherited prion diseases caused by different PRNP mutations include fatal familial insomnia and Gerstmann-Sträussler-Scheinker disease.
Iatrogenic CJD
This form results from accidental medical transmission. Historically, cases have been traced to contaminated surgical instruments, corneal transplants, and human growth hormone extracted from the pituitary glands of deceased donors. Modern screening and synthetic hormone production have made new cases extremely rare.
Variant CJD
Variant CJD (vCJD) is linked to consuming beef products from cattle infected with bovine spongiform encephalopathy, commonly known as mad cow disease. An outbreak of BSE swept through British cattle herds in the late 1980s and early 1990s, and a new, distinct form of CJD subsequently appeared in younger people in the United Kingdom. Unlike sporadic CJD, which primarily affects older adults, vCJD has struck people in their 20s and 30s. Strict regulations on animal feed and meat processing have dramatically reduced the risk, and new cases of vCJD are now exceptionally rare.
Symptoms and How They Progress
CJD typically begins with vague symptoms that can mimic many other conditions. In the earliest stages, people may experience fatigue, headaches, dizziness, and disrupted sleep. Memory problems, mood swings, irritability, depression, and visual changes also appear early on. Because these symptoms are so nonspecific, CJD is often not suspected at first.
The disease then accelerates. Confusion and disorientation worsen noticeably over weeks rather than years, which is one of the key distinctions from other dementias like Alzheimer’s. Movement problems emerge: difficulty with coordination, muscle stiffness, and involuntary jerky movements called myoclonus. These jerking movements can persist during sleep and may be triggered by loud sounds or bright lights.
In the later stages, people develop slowed movement, abnormal postures, and increasing rigidity. They gradually lose the ability to walk, then to speak. Eventually, patients enter a comatose state. The full course from first symptom to death is often just a few months for sporadic CJD, though variant CJD tends to progress somewhat more slowly, sometimes over 12 to 14 months.
How CJD Is Diagnosed
Diagnosing CJD relies on a combination of clinical evaluation, brain imaging, and laboratory tests. No single test is definitive on its own during life, but together they can provide a high degree of certainty.
Brain MRI is one of the most useful tools. In sporadic CJD, imaging often reveals abnormal bright signals in the cortex and deep brain structures. Variant CJD produces a distinctive pattern: a bright signal in the pulvinar, a region at the back of the thalamus. When this signal also lights up an adjacent area called the dorsomedial thalamic nucleus, it creates a shape often described as a “hockey stick” on the scan. This pattern is highly characteristic of vCJD and helps distinguish it from other forms.
A spinal fluid test called RT-QuIC has become a game-changer for diagnosis. It works by detecting the ability of misfolded prions in a patient’s spinal fluid to convert normal prion proteins in a lab setting, essentially catching the chain reaction in action. In prospective studies, this test has shown 96 percent sensitivity and 100 percent specificity for sporadic CJD when using spinal fluid alone. When combined with a nasal swab sample, sensitivity reaches 100 percent with no false positives. This level of accuracy has made RT-QuIC a cornerstone of modern CJD diagnosis.
Electroencephalography (EEG) can also reveal characteristic patterns of brain activity in some forms of CJD, though it is less reliable than MRI or RT-QuIC.
Treatment and Ongoing Research
There is currently no cure for CJD, and no treatment can slow or stop the progression of the disease. Care focuses on managing symptoms and keeping patients as comfortable as possible.
However, active clinical trials are testing new approaches. Two first-in-human studies are currently enrolling patients in the United States. One is investigating a drug called ION717, delivered directly into spinal fluid, that is designed to reduce the production of the prion protein itself. This randomized, blinded trial tests multiple dose levels over a 24-week treatment period with 36 weeks of follow-up. A second trial, called PRiSM, uses a different molecular strategy with the same goal: silencing the gene that produces the prion protein so there is less raw material for the misfolding chain reaction. Both approaches represent a fundamental shift from symptom management to targeting the root cause.
These trials are still in early stages, focused primarily on safety. But they mark the first time therapies designed to directly interfere with prion biology have reached human testing, which is a meaningful step for a disease that has had no treatment options for decades.
Why CJD Progresses So Quickly
People often wonder why CJD moves so much faster than other neurodegenerative diseases. The answer lies in the nature of the prion chain reaction. Unlike the slow protein buildup seen in Alzheimer’s or Parkinson’s, prion conversion is exponential. Each newly misfolded protein can recruit more normal proteins, and the resulting aggregates are essentially invisible to the immune system. The body has no antibody response, no inflammatory alarm that could slow things down. By the time symptoms appear, widespread brain damage is already underway. This combination of rapid self-replication and immune evasion makes CJD one of the most aggressive neurological diseases known.